TY - JOUR
T1 - The practical synthesis of a methylenebisphosphonate analogue of benzamide adenine dinucleotide
T2 - Inhibition of human inosine monophosphate dehydrogenase (type I and II)
AU - Pankiewicz, K. W.
AU - Lesiak, K.
AU - Zatorski, A.
AU - Goldstein, B. M.
AU - Carr, S. F.
AU - Sochacki, M.
AU - Majumdar, A.
AU - Seidman, M.
AU - Watanabe, K. A.
PY - 1997/5/6
Y1 - 1997/5/6
N2 - β-Methylene-BAD (8), a nonhydrolyzable analogue of benzamide adenine dinucleotide (BAD), was synthesized as potential inhibitor of human inosine monophosphate dehydrogenase (IMPDH). Treatment of 2',3'O- isopropylideneadenosine 5'-methylenebisphosphonate (15) with DCC afforded P1,P4-bis(2',3'-O-isopropylideneadenosine) 5'-P1,P2:P3,p4- dimethylenetetrakisphosphonate (17). This compound was further converted with DCC to an active intermediate 18 which upon reaction with 3.(2',3'-O- isopropylidene-β-D-ribofuranosyl)benzamide (19) gave, after hydrolysis and deisopropylidenation, the desired β-methylene-BAD (8) in'95% yield. In a similar manner, treatment of 18 with 2',3'-O-isopropylidenetiazofurin (21) followed by hydrolysis and aleprotection afforded β-methylene-TAD (5) in 91% yield. Compound 8 (IC50 = 0.665 μM) was found to be a 6-8 times less potent inhibitor of IMPDH than 5 (IC50 = 0.107 μM) and was almost equally potent against IMPDH type I and type II. Although TAD and β-methylene-TAD were bound by LADH with the same affinity, the binding affinity of 8 toward LADH (K(i) = 333 μM) was found to be 50-fold lower than that of the parent pyrophosphate 7 (K(i) = 6.3 μM).
AB - β-Methylene-BAD (8), a nonhydrolyzable analogue of benzamide adenine dinucleotide (BAD), was synthesized as potential inhibitor of human inosine monophosphate dehydrogenase (IMPDH). Treatment of 2',3'O- isopropylideneadenosine 5'-methylenebisphosphonate (15) with DCC afforded P1,P4-bis(2',3'-O-isopropylideneadenosine) 5'-P1,P2:P3,p4- dimethylenetetrakisphosphonate (17). This compound was further converted with DCC to an active intermediate 18 which upon reaction with 3.(2',3'-O- isopropylidene-β-D-ribofuranosyl)benzamide (19) gave, after hydrolysis and deisopropylidenation, the desired β-methylene-BAD (8) in'95% yield. In a similar manner, treatment of 18 with 2',3'-O-isopropylidenetiazofurin (21) followed by hydrolysis and aleprotection afforded β-methylene-TAD (5) in 91% yield. Compound 8 (IC50 = 0.665 μM) was found to be a 6-8 times less potent inhibitor of IMPDH than 5 (IC50 = 0.107 μM) and was almost equally potent against IMPDH type I and type II. Although TAD and β-methylene-TAD were bound by LADH with the same affinity, the binding affinity of 8 toward LADH (K(i) = 333 μM) was found to be 50-fold lower than that of the parent pyrophosphate 7 (K(i) = 6.3 μM).
UR - http://www.scopus.com/inward/record.url?scp=0030907934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030907934&partnerID=8YFLogxK
U2 - 10.1021/jm960641y
DO - 10.1021/jm960641y
M3 - Article
C2 - 9111303
AN - SCOPUS:0030907934
SN - 0022-2623
VL - 40
SP - 1287
EP - 1291
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 8
ER -